Top Markets
#1 Islamic Coin Islamic Coin +152.25%
#2 Bitway Bitway +40.84%
#3 Wrapped STX (Velar) Wrapped STX (Velar) +38.17%
#4 Starpower Starpower +29.00%
#5 Pleasing Gold Pleasing Gold +28.64%
#6 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +24.29%
#7 Pons Pons +22.64%
#8 aelf aelf +18.42%
#9 Decred Decred +14.29%
#10 Venom Venom +14.02%
Coin of the day
Islamic Coin Islamic Coin
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Proteomics International Laboratories Ltd. Proteomics International Laboratories Ltd.

Proteomics International Laboratories Ltd.

PIQ
Classement en actions #30001
Proteomics International Laboratories Ltd operates as a medical technology... Proteomics International Laboratories Ltd operates as a medical technology company with a focus on the area of proteomics in Australia, New Zealand, the United States, Europe, India, and Southeast Asia. It provides PromarkerD, a blood test to predict diabetic kidney disease (DKD). The company’s products under development include PromarkerEndo, which has completed clinical validation phase for endometriosis diagnosis; PromarkerEso, which has completed clinical validation trials for esophageal cancer diagnosis; and OxiDx (2-tag), which has completed clinical validation phase for oxidative stress treatment. It is also developing diagnostic tests for that includes DKD - T1D, that is under clinical phase for type 1 diabetes, diabetic retinopathy, and diabetic neuropathy; Asthma and COPD, which has completed proof-of-concept study trials for asthma and chronic obstructive pulmonary disease; Plant Dieback, that is under development phase for phytophthora dieback; Diabetic Retinopathy, which has completed discovery phase for sight-threatening retinopathy; and Diabetic Neuropathy, that is under research phase to investigate predictive biomarkers for diabetic neuropathy. The company also offers analytical services, such as specialist contract research focusing on biomarker discovery, biosimilars quality control, and pharmacokinetic testing for clinical trials. It has strategic collaboration with Harry Perkins Institute of Medical Research, Bioplatforms Australia, The University of Western Australia, Australian Research Council Training Centre, and the Australian Centre. Proteomics International Laboratories Ltd was founded in 2001 and is based in Perth, Australia.
Prix de l'action
$0.11284557
Capitalisation boursière
$18.66M
Changement (1 jour)
3.23%
Changement (1 an)
-47.82%
Pays
AU
Échange Proteomics International Laboratories Ltd. (PIQ)

Catégorie

Healthcare
Bénéfices pour Proteomics International Laboratories Ltd. (PIQ)
Bénéfices en 2026 TTM : 0
Selon les derniers rapports financiers de Proteomics International Laboratories Ltd., les bénéfices actuels de l'entreprise sont de 0. En 2026, l'entreprise a réalisé un bénéfice de 0, égal à celui de 2026 qui était de 0. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour Proteomics International Laboratories Ltd. de 2026 à 2026
Bénéfices à la fin de chaque année
Année Bénéfices Changez
Pas assez de données pour les dates fournies.
Bénéfices des entreprises similaires ou concurrentes
Entreprise Bénéfices Différence de bénéfices Pays
HCA Healthcare, Inc. HCA Healthcare, Inc.
HCA Healthcare, Inc.
HCA.US
$9.87B -
US
Fresenius SE & Co. KGaA Fresenius SE & Co. KGaA
Fresenius SE & Co. KGaA
FRE.DE
- -
DE
Dr. Sulaiman Al Habib Medical Services Group Company Dr. Sulaiman Al Habib Medical Services Group Company
Dr. Sulaiman Al Habib Medical Services Group Company
4013.SR
$687.82M -
SA
Tenet Healthcare Corporation Tenet Healthcare Corporation
Tenet Healthcare Corporation
THC.US
$3.87B -
US
IHH Healthcare Berhad IHH Healthcare Berhad
IHH Healthcare Berhad
5225.KL
- -
MY